Listing Regulation | Nanologica

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

30 January, 2026

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till extra bolagsstämma onsdagen den 4 mars 2026, klockan 10.00, i Advokatfirman Lindahls lokaler, på Smålandsgatan 16, Stockholm. Rätt att delta vid stämman Aktieägare som önskar delta i bolagsstämman ska: dels vara registrerad i eget namn (inte förvaltarregistrerad) i den av Euroclear Sweden AB förda aktieboken tisdagen den 24 februari 2026, dels anmäla sitt deltagande så att anmälan är Bolaget tillhanda senast torsdagen den 26

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

30 January, 2026

The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the "Company") are hereby invited to attend the Extraordinary General Meeting to be held on Wednesday, March 4, 2026, at 10.00 a.m. CET at Advokatfirman Lindahl's premises, at Smålandsgatan 16, Stockholm. Right to participate in the meeting Shareholders who wish to participate in the Extraordinary General Meeting must: be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on Tuesday,

Delårsrapport Q3 2025 Nanologica AB (publ)

23 October, 2025

FINANSIELL SAMMANFATTNING Nettoomsättningen för tredje kvartalet uppgick till 2 843 TSEK (611) och för niomånaders-perioden till 15 930 TSEK (7 822) Rörelseresultatet för kvartalet uppgick till -10 017 TSEK (-22 203) och för niomånadersperioden till -30 021 TSEK (-47 365) Resultatet före skatt för kvartalet uppgick till -10 998 TSEK (-23 701) och för niomånadersperioden till -33 481 TSEK (-51 561) Resultat per aktie före och efter utspädning var -0,12 SEK (-0,54) för kvartalet och -0,38 SEK

Interim Report Q3 2025 Nanologica AB (publ)

23 October, 2025

FINANCIAL SUMMARY Net sales for the third quarter amounted to SEK 2,843 thousand (611) and for the nine-month period to SEK 15,930 thousand (7,822) Operating loss for the quarter amounted to SEK -10,017 thousand (-22,203) and for the nine-month period to SEK -30,021 thousand (-47,365) Loss before tax for the quarter amounted to SEK -10,998 thousand (-23,701) and for the nine-month period to SEK -33,481 thousand (-51,561) Earnings per share before and after dilution were

NANOLOGICAS VALBEREDNING UTSEDD INFÖR ÅRSSTÄMMAN 2026

14 October, 2025

I enlighet med gällande valberedningsinstruktion har styrelsens ordförande kontaktat Nanologicas tre röstmässigt största ägare eller ägargrupper per den 30 september 2025, som var och en har erbjudits att utse en representant att utgöra valberedning i Nanologica AB inför årsstämman 2026. Valberedningen inför Nanologica AB:s årsstämma 2026 utgörs därmed av följande tre ledamöter: Carl-Johan Spak (Flerie Invest AB) Niklas Sjöblom (Konstakademiens stiftelser) Kalle Olby (Vega Bianca AB) Valberedningen representerar tillsammans 53,0 procent av röstetalet för samtliga

NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2026

14 October, 2025

In accordance with the current nomination committee instructions, the chairman of the board has contacted Nanologica's three largest shareholders or owner groups in terms of voting rights as of September 30, 2025, each of whom has been offered to appoint a representative to constitute the nomination committee of Nanologica AB for the 2026 Annual General Meeting. The nomination committee for Nanologica AB's AGM 2026 thus consists of the following three members: Carl-Johan Spak (Flerie Invest

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.